Answer
Patients receiving CRESEMBA (isavuconazonium sulfate) should avoid driving or operating machinery if they experience confusion, somnolence, syncope or dizziness.
Sources for this answer
- CRESEMBA 200mg Powder for concentrate for solution for infusionPfizer Limited · emc · SmPC §4.7 Effects on ability to drive and use machines · Version 22Document updated
Sources checked